Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, is pleased to announce the appointment of Germo Gericke, M.D., as Chief Medical Officer.
Germo joins Ariceum from Novartis, where he has recently served as Chief Medical Officer and Global Head of Research and Development at Advanced Accelerator Applications (AAA), a Novartis company specializing in the field of nuclear medicine. Germo will be based at Ariceum’s newly opened subsidiary in Basel, Switzerland. Basel offers one of the largest talent pools in Europe for the development and commercialization of innovative pharmaceuticals.
Manfred Rüdiger, PhD, Chief Executive Officer of Ariceum Therapeutics, said: “I am delighted to welcome Germo to the Ariceum leadership team at a pivotal time of Company growth and clinical development. Germo brings with him a wealth of experience in the field of radiopharmaceutical therapy and it is a testament to the potential of Ariceum’s theranostic portfolio that someone of Germo’s calibre has chosen to join our team. Germo will build and lead the clinical development and operations team out of our new subsidiary in Basel.”
Germo Gericke, M.D., Chief Medical Officer of Ariceum Therapeutics, commented: “I am excited to join Ariceum with its focus on systemic targeted radiotherapy. Ariceum is actively working to develop innovative medicines for the diagnosis, monitoring, and precision treatment of certain aggressive neuroendocrine cancers, such as small cell lung cancer (SCLC). These cancers have few treatment options and poor prognoses, and so I look forward to contributing to Ariceum’s mission to improve the lives of those facing these very challenging diseases.”
Germo joins Ariceum from Advanced Accelerator Applications (AAA), a Novartis company developing targeted radioligand therapies and precision imaging radioligands for oncology indications. As a member of the Executive Leadership Team, he held positions of Chief Medical Officer and Head of Research and Development building a global R&D organization for Radioligand Therapies. Prior to AAA, Germo served as Franchise Global Program Head in Oncology Development and in strategic, commercial and general management roles with increasing responsibility across a range of therapeutic and geographic areas, having joined Novartis in 2001 from McKinsey & Company. Germo studied medicine at Charité University Hospital in Berlin and holds an MD from the University of Heidelberg.